Krystal Biotech, Inc.

NasdaqGS KRYS

Krystal Biotech, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD 63.34 M

Krystal Biotech, Inc. Operating Cash Flow is USD 63.34 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 160.97% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Krystal Biotech, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -103.90 M, a -4.80% change year over year.
Krystal Biotech, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -99.14 M, a -182.76% change year over year.
Krystal Biotech, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -35.06 M, a -39.66% change year over year.
Krystal Biotech, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -25.11 M, a -65.33% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqGS: KRYS

Krystal Biotech, Inc.

CEO	Mr. Krish S. Krishnan M.B.A., M.S.
IPO Date	Sept. 20, 2017
Location	United States
Headquarters	2100 Wharton Street
Employees	229
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Key trends

Past 5 years